113 related articles for article (PubMed ID: 11548847)
1. Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells.
Osma MM; Ortuño F; Lozano ML; Gomez-Espuch J; Ayala F; Sanchez-Serrano I; Perez-Ceballos E; Moraleda JM; Vicente V
Bone Marrow Transplant; 2001 Jun; 27(12):1287-92. PubMed ID: 11548847
[TBL] [Abstract][Full Text] [Related]
2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
3. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor.
Johnsen HE; Hansen PB; Plesner T; Jensen L; Gaarsdal E; Andersen H; Hansen SW; Birgens H; Jacobsen GK; Kjaersgaard E
Bone Marrow Transplant; 1992 Sep; 10(3):229-34. PubMed ID: 1384899
[TBL] [Abstract][Full Text] [Related]
4. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
Hansen PB; Knudsen H; Gaarsdal E; Jensen L; Ralfkiaer E; Johnsen HE
Bone Marrow Transplant; 1995 Sep; 16(3):373-9. PubMed ID: 8535309
[TBL] [Abstract][Full Text] [Related]
5. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
6. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
[TBL] [Abstract][Full Text] [Related]
7. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
Carlo-Stella C; Di Nicola M; Milani R; Guidetti A; Magni M; Milanesi M; Longoni P; Matteucci P; Formelli F; Ravagnani F; Corradini P; Gianni AM
Blood; 2004 May; 103(9):3287-95. PubMed ID: 14726397
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
9. [Effects of recombinant human interleukin 11 and granulocyte colony stimulating factor in mobilization for autologous peripheral blood stem cell transplantation].
Zhu HY; DA WM; Gao CJ; Wang FF; Han XP; Li HH; Huang WR; Zhang YZ; Wang SH; Bo J; Jing Y; Jin HJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):345-9. PubMed ID: 18426662
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
11. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
[TBL] [Abstract][Full Text] [Related]
12. [In vivo effect of rhG-CSF on the CXCR-4 expression of hematopoietic progenitor or stem cells in bone marrow and peripheral blood].
Zhao XY; Chang YJ; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):857-60. PubMed ID: 16277858
[TBL] [Abstract][Full Text] [Related]
13. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
14. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.
Demirer T; Ayli M; Dagli M; Haznedar R; Genc Y; Fen T; Dincer S; Unal E; Gunel N; Seyrek E; Ustun T; Ustael N; Yildiz M; Sertkaya D; Ozet G; Muftuoglu O
Br J Haematol; 2002 Sep; 118(4):1104-11. PubMed ID: 12199792
[TBL] [Abstract][Full Text] [Related]
15. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
[TBL] [Abstract][Full Text] [Related]
16. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.
Benboubker L; Cartron G; Roingeard F; Delain M; Degenne M; Linassier C; Hérault O; Truglio D; Bout M; Petit A; Brémond JL; Desbois I; Colombat P; Binet C; Domenech J
Exp Hematol; 2003 Jan; 31(1):89-97. PubMed ID: 12543111
[TBL] [Abstract][Full Text] [Related]
17. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.
Demirer T; Ayli M; Ozcan M; Gunel N; Haznedar R; Dagli M; Fen T; Genc Y; Dincer S; Arslan O; Gürman G; Demirer S; Ozet G; Uysal A; Konuk N; Ilhan O; Koc H; Akan H
Br J Haematol; 2002 Feb; 116(2):468-74. PubMed ID: 11841454
[TBL] [Abstract][Full Text] [Related]
18. Immune recovery after autologous or rhG-CSF primed PBSC transplantation.
Rosillo MC; Ortuño F; Moraleda JM; Lozano ML; Heras I; De Arriba F; Vicente V
Eur J Haematol; 1996 May; 56(5):301-7. PubMed ID: 8641404
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation.
Bensinger WI; Longin K; Appelbaum F; Rowley S; Weaver C; Lilleby K; Gooley T; Lynch M; Higano T; Klarnet J
Br J Haematol; 1994 Aug; 87(4):825-31. PubMed ID: 7527244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
